株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

手足口病 : パイプライン分析

Hand, Foot and Mouth Disease - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302505
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
手足口病 : パイプライン分析 Hand, Foot and Mouth Disease - Pipeline Review, H2 2016
出版日: 2016年11月30日 ページ情報: 英文 36 Pages
概要

手足口病(HFMD)とは、口の内部や手・足・脚部の上に痛みが生じるという疾患です。腸内ウイルス類の一種であるコクサッキーウイルスA16が主な感染源となっています。主な症状として、発熱や頭痛、食欲不振、喉(扁桃腺を含む)・口・舌の痛みなどが挙げられています。主な治療法には、抗生物質や鎮痛剤などがあります。

当レポートでは、世界各国での手足口病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

手足口病の概要

治療薬の開発

  • 手足口病向けパイプライン製品:概要
  • 手足口病向けパイプライン製品:比較分析

各企業で開発中の手足口病治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

手足口病治療薬:開発中の製品の一覧(企業別)

手足口病治療薬の開発に従事している企業

  • Chongqing Zhifei Biological Products Co., Ltd.
  • CJ CheilJedang Corp.
  • iQur Limited
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • 武田薬品工業

手足口病:治療薬の評価

  • 単剤製品
  • 併用製品
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • CJ-40010
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • coxsackievirus serotype A16 + enterovirus serotype 71 ワクチン
  • D-5
  • enterovirus serotype 71 vaccine
  • 手足口病 ウイルス様粒子ワクチン
  • 手足口病 ウイルス様粒子ワクチン
  • 手足口病(2価)ウイルス様粒子ワクチン
  • TAK-021

手足口病治療薬:パイプライン製品の最新動向

手足口病関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8747IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.

Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.Hand, Foot and Mouth Disease.

Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hand, Foot and Mouth Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hand, Foot and Mouth Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hand, Foot and Mouth Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hand, Foot and Mouth Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hand, Foot and Mouth Disease Overview
  • Therapeutics Development
    • Pipeline Products for Hand, Foot and Mouth Disease - Overview
    • Pipeline Products for Hand, Foot and Mouth Disease - Comparative Analysis
  • Hand, Foot and Mouth Disease - Therapeutics under Development by Companies
  • Hand, Foot and Mouth Disease - Therapeutics under Investigation by Universities/Institutes
  • Hand, Foot and Mouth Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hand, Foot and Mouth Disease - Products under Development by Companies
  • Hand, Foot and Mouth Disease - Products under Investigation by Universities/Institutes
  • Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development
    • CJ HealthCare Corp
    • Sentinext Therapeutics Sdn Bhd
    • Takeda Pharmaceutical Company Ltd
  • Hand, Foot and Mouth Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-40010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-07090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hand, foot and mouth disease (viral like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hand, Foot and Mouth Disease - Dormant Projects
  • Hand, Foot and Mouth Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016
  • Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hand, Foot and Mouth Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016
  • Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top